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The antibiotic G418 was shown to be an effective inhibitor of vaccinia virus replication when an appropriate
concentration of it was added to cell monolayers 48 h before infection. Genetic engineering techniques were
used in concert with DNA transfection protocols to construct vaccinia virus recombinants containing the
neomycin resistance gene (neo) from transposon TnS. These recombinants contained the neo gene linked in
either the correct or incorrect orientation relative to the vaccinia virus 7.5-kilodalton gene promoter which is
expressed constitutively throughout the course of infection. The vaccinia virus recombinant containing the
chimeric neo gene in the proper orientation was able to grow and form plaques in the presence of G418,
whereas both the wild-type and the recombinant virus with the neo gene in the opposite polarity were inhibited
by more than 98%. The effect of G418 on virus growth may be mediated at least in part by selective inhibition
of the synthesis of a subset of late viral proteins. These results are discussed with reference to using this system,
the conferral of resistance to G418 with neo as a positive selectable marker, to facilitate constructing vaccinia
virus recombinants which contain foreign genes of interest.
The use of cloning and expression vectors to study and
experimentally manipulate individual genes independently of
their normal resident environment has become a central and
vital theme in molecular genetics. Due to a number of unique
biological attributes, vaccinia virus (VV) would seem to offer
an ideal system for such studies (12). A number of laborato-
ries have demonstrated the feasibility of this approach by
constructing recombinant VV strains which contain and
express heterologous viral and cellular antigens (13, 15, 16).
Such hybrid strains may prove useful in the preparation of
vaccines against a variety of human and animal diseases.
Unfortunately the current methods used to construct VV
recombinants are slow, time-consuming, and expensive and
do not facilitate genetic engineering of the foreign DNA
insert. These drawbacks have thus far retarded the develop-
ment of VV as a general eucaryotic expression vector. The
chief limitation of this system stems from the fact that the
methods used to detect and isolate VV recombinants of
interest rely on unsophisticated screening procedures (20).
One major improvement has been provided by Mackett et
al., who developed a VV insertion vector which inserts
foreign genes into the middle of the VV thymidine kinase (tk)
gene (11). This results in functional inactivation of tk activity
and converts the recombinant virus to a tk- phenotype. In
principle, it should be possible to select recombinants meta-
bolically with bromodeoxyuridine. However, the spontane-
ous rate of tk- mutants arising in the virus population is
quite high, on the order of 10-3 to 10-4, so that recombinant
VV still makes up only a fraction of the total tk- population
(D. E. Hruby, unpublished data). This is particularly trou-
blesome if one is attempting to insert a large foreign gene
which will be rescued at a low frequency. Thus, although the
use of bromodeoxyuridine is certainly a useful enrichment
technique, it does not provide a direct selection for re-
combinants. These problems could be circumvented if meth-
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ods were developed to employ dominant selectable markers
for isolating VV recombinants.
An appropriate strategy might be the construction of
tandem plasmid insertion vectors with a selectable marker
linked to a foreign gene of interest. This would consist of a
VV promoter (P1) linked to a polylinker region for the
insertion of foreign genes, and a second VV promoter (P2)
linked to a selectable marker, with the entire tandem ar-
rangement embedded in VV DNA sequences sufficient to
catalyze recombination into a nonessential region of the viral
genome. Such a plasmid could be used to insert the tandem
genes into the VV genome. Recombinants could then be
selected directly by using biochemical agents.
There are a number of positive selection schemes which
could potentially be adapted to the VV system, but the two
with the greatest promise would seem to be selection of the
tk+ phenotype with methotrexate (21) and of the Neor
phenotype with G418 (18). Methotrexate has previously
been used to select VV recombinants with a tk+ phenotype
that resulted from the insertion of a functional viral tk gene
into a VV tk- mutant (21). In analogy to selecting for tk-
VV, it might be anticipated that the number of tk+ revertants
would be equal to or greater than the number of tk+ VV
arising from recombination. This problem could be circum-
vented by using a VV mutant containing a deletion in the tk
region (11). An alternative approach would be the use of
G418. The synthetic antibiotic G418, which is an effective
inhibitor of protein synthesis in both eucaryotic and procary-
otic systems, has been used as a selective agent for trans-
formants that have taken up and are expressing the bacterial
neomycin resistance gene, neo (18). This system is particu-
larly powerful because no equivalent enzymatic activity
exists in eucaryotic cells and therefore there is no back-
ground of spontaneous G418-resistant mutants. In the ex-
periments reported here, we have sought to determine
whether the G418-neo system could be used to select VV
recombinants, specifically, whether VV replication in tissue
culture cells is inhibited by the drug, and if so whether the
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inhibition could be overcome by a VV recombinant which
contained and expressed a functional neo gene.
MATERIALS AND METHODS
Cells and virus. VV (WR strain) was grown and its titers
were determined on monolayers of BSC-40 cells maintained
in Eagle minimal essential medium supplemented with 10%o
heat-inactivated fetal calf serum, 2 mM L-glutamine, and 10
pg of gentamicin sulfate per ml (7). Transfections were
carried out on Ltk- cells grown in the same medium. Media
containing G418 (GIBCO Diagnostics) were prepared by
dissolving an appropriate amount of the drug in the medium
and then passing the solution through a filter (0.22-.im pore
size; Millipore Corp.).
Plasmid construction. The construction of pVV5.1 will be
described in detail elsewhere (manuscript in preparation).
Briefly, the XbaI-XhoI fragment of pGS20 (11) which con-
tains the VV 7.5-kilodalton (7.5Kd) gene promoter region
embedded within the VV tk coding region was ligated into
pMT21, a small ampicillin-resistant (Amp') derivative of
pBR322 (obtained from Henry V. Huang). The XhoI and
XbaI sites flanking the VV insert, as well as the ClaI site in
the tk gene, were removed during the construction. pVV5.1
contained the following restriction sites, beginning 40
nucleotides downstream from the start of VV 7.5Kd pro-
moter early transcription: XhoI, EcoRI, SmaI, BamHI, PstI,
SmaI, and EcoRI. This plasmid was linearized with BamHI,
treated with calf intestinal alkaline phosphatase, and ligated
to the BamHI-BgIII fragment of pBRNEO, which contained
CG4183.qmimI
FIG. 1. Effect of increasing concentrations of G418 on VV
replication. G418 was added to the cells 48 h before infection and
maintained throughout the experiment. Cells were infected with VV
at a multiplicity of 5 PFU/cell. After 24 h of infection, the progeny
virions were harvested and the titer was determined in the absence
of drug. The control titer in the absence of drug was 1.22 x 101
PFU/ml.
TABLE 1. Effect of adding G418 at different times before VV
infectiona
G418 concn Time of addition VV titer % Inhibition
(mg/ml) (h preinfection) (PFU/ml) of growth
0 (control) 2.45 x 107
1 0 7.82 x 106 68.1
12 7.20 x 106 70.6
24 5.54 x 106 77.4
36 5.39 x 106 78.0
48 5.14 x 106 79.0
2 0 3.92 x 106 84.0
12 2.55 x 106 89.6
24 1.69 x 106 93.1
36 1.57 x 106 93.6
48 1.20 x 106 95.1
a Cells were pretreated wtih G418 for the indicated periods. The monolay-
ers were infected with wild-type VV at a multiplicity of 5 PFU/cell. Drug-
containing medium was returned to the infected cells, and infection was
allowed to proceed at 37°C for 24 h. Progeny VV were then harvested and
titers were determined.
the neomycin resistance gene from Tn5 (3). Plasmids were
obtained with the gene in both orientations and were desig-
nated pVV:NEb (correct orientation) and pVV:lEO (op-
posite orientation).
Marker rescue. The insertion of the neo gene into the VV
genome was performed essentially by the method described
elsewhere (submitted for publication). The recombinant
plasmids were coprecipitated with wild-type VV DNA and
carrier salmon sperm DNA by using calcium orthophosphate
(6). The precipitated DNAs were transfected into Ltk- cells
3 h after they were infected with VV at a multiplicity of 0.05
PFU/cell. The infected-cell monolayers were shocked with
glycerol for 40 s to facilitate DNA uptake (10) and then
incubated at 37°C for 48 h. The progeny of this initial marker
rescue step were then passaged through Ltk- cells in the
presence of bromodeoxyuridine (25 ,ug/ml) to amplify the
number of tk- VV in the population. Recombinant VV
containing the neo gene were then detected by plaque
hybridization with a nick-translated BglII-BamHI neo DNA
fragment as the probe (3). Individual recombinant plaques
were punched out from replica nitrocellulose filters and
inoculated into 24-well dishes of BSC-40 cells. After 48 h,
cell extracts were prepared by trypsinizing the infected cells.
A portion of each extract was subjected to dot blot analysis
(10) to confirm that VV containing the neo gene were
present. Virus from extracts scored as positive were then
subjected to an additional round of plaque purification and
grown on a larger scale.
DNA analysis. DNA was extracted and purified from
cytoplasmic extracts of BSC-40 cells infected at a multiplic-
ity of 10 PFU/cell with putative VV recombinants (submitted
for publication). The DNA was digested with various restric-
tion endonucleases, and the fragments were resolved by
electrophoresis in 0.8% agarose gels (14). After being stained
with 0.5 ,ug of ethidium bromide per ml, the gels were
photographed, blotted onto nitrocellulose, and hybridized
with appropriate nick-translated DNA fragments as probes
(17). In all cases, wild-type VV DNA was run as a control.
Reference was made to previously published restriction
maps of VV DNA (4), as well as to unpublished data from
our own laboratory, to determine the genomic structure of
the VV recombinants.
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FIG. 2. Construction of the VV:NEO recombinant plasmids. VV DNA sequences are indicated by heavy lines. The position of the VV
7.5Kd gene promoter (P) is indicated. CIAP, Calf intestinal alkaline phosphatase; Ori, origin of replication.
Protein synthesis. Monolayers of BSC-40 cells in 60-mm
dishes were infected at a multiplicity of 10 PFU/cell with
wild-type or recombinant VV. The infected cells were either
pulse-labeled for 30 min with 20 jxCi of L-[5S]methionine
(1,140 Ci/mmol; New England Nuclear Corp.) at the indi-
cated times postinfection or continuously labeled by having
5 jCi of radioactive label per ml present throughout the
infection. The radioactively labeled infected cells were har-
vested and collected by centrifugation. The pellets were
suspended in 100 ,ul of 1 mM Tris-hydrochloride (pH 9), and
a small portion was used to determine the hot trichloroacetic
acid-precipitable counts. Equivalent amounts of radio-
actively labeled cell lysates were then analyzed on 12%
sodium dodecyl sulfate-polyacrylamide slab gels (19). The
gels were then impregnated with 2,5-diphenyloxazole and
fluorographed at -70°C on Kodak XAR-5 film (1).
RESULTS
G418 inhibition ofW growth. Previous experiments have
shown that high levels ofG418 (1 to 2 mg/ml) must be present
for a substantial period of time (24 to 48 h) to inhibit the
replication of mammalian cells and that different cell lines
differ widely in their sensitivity to this drug (18). Since VV
macromolecular synthesis occurs within the cytoplasmic
compartment of infected cells and utilizes the host cell
translational apparatus (8), it seemed likely that these con-
siderations would also apply to G418 inhibition of viral
growth. Therefore, the effect of increasing concentrations of
G418 on the yield of VV progeny from one-step infections
carried out on BSC-40 cell monolayers was assayed (Fig. 1).
VV replication was sensitive to G418-mediated inhibition,
being reduced 95% by a concentration of 2 mg/ml. Under
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these conditions, VV plaque formation w
abolished. The time of treatment required
inhibit VV growth was also examined (Tabl
the effects observed were not dramatic, there
reduction of VV growth which correlated wi
cells had been treated with G418, from 0 1
infection. Based on these results, the stand
used for the rest of the experiments reported I
at 2 mg/ml added 48 h before infection and ma
concentration throughout the infection. Und
tions, the cells appeared normal and VV r
essentially blocked. Similar results were obi
host cells. For example, a 48-h treatment of ]
2 mg of G418 per ml resulted in 97.3% inl
growth.
Construction of VV:NEO recombinants.
whether the inhibition of VV replication by
overcome by the neomycin resistance gene
rescue techniques were used to isolate VV
containing this gene. Figure 2 shows the rec
mids that were constructed to mobilize the ne
VV genome. The neo gene from transposo
inserted into the VV insertion vector pVVJ
correct (--) and incorrect (+-) orientation rek
7.5Kd gene promoter, which is expressed bot]
during infection (11). The flanking VV DI
allowed these chimeric genes to be recomi
resident VV tk gene by transfecting them intc
of VV-infected cells (submitted for publicati
VV recombinants were detected and isola
hybridization and several rounds of plaque pi
genomic analysis of these recombinants is si
The pattern of VV DNA fragments gener
showed that the 5.2-kilobase (kb) Sall M fragi
wild-type DNA was replaced in the two
I 3: Z sZ
..>> >>
> >A
Kb
to
B > > > C > > >
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67-
44-
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20-
FIG. 3. Genomic structure of VV:NEO recor
from wild-type (WT) VV, VV:NEb, and VV:IE
with Sall and analyzed by agarose gel electrophores
fragments were then transferred to nitrocellulose
nick-translated VV HindIII-J DNA (B) or neo DNI
the orientations, the parental plasmid and viral DN
digested with XhoI-RsaI and subjected to Southe
with nick-translated neo DNA as the probe (D).
lambda DNA fragments digested with HindIII rur
indicated to the left of each panel.
(as completely
to effectively
Le 1). Although
was a general
th the time the
to 48 h before
lard conditions
here were G418
intained at this
er these condi-
eplication was
tained in other
Ltk- cells with
TABLE 2. One-step growth of VV:NEO in the presence of G418'
Titer (PFU/ml) % Inhibition
VVstrainofgwtInitial Without G418 With G418 of growth
Wild type 4.8 x 106 5.6 x 108 5.2 x 106 99.1
VV:NEO 3.0 x 106 4.6 x 108 4.4 x 108 4.3
VV:}iE 1.9 x 106 3.7 x 108 4.6 x 106 98.8
a Infections were carried out at an input of 5 PFU/cell on monolayers of
BSC-40 cells (7) which had been incubated for the previous 48 h with or
without G418 (2 mg/ml). After a 24-h infection, the progeny VV were
harvested and counted.
hibition of VV combinants by two new fragments of 5.8 and 0.6 kb (Fig.
3A). The new fragments were expected as a result of the
To ascertain insertion of the 1.2-kb chimeric 7.5Kd promoter:neo gene,
G418 could be which contained a single new Sall site within the promoter
(neo), marker region. The identity of the new fragments was confirmed by
recombinants Southern analyses. Nick-translated VV HindIII-J DNA,
ombinant plas- which contained the VV tk gene, hybridized to Sall M
?o gene into the fragment as well as to the two new VV:NEO-derived bands
in TnS (3) was (Fig. 3B). In contrast, when labeled neo DNA was used as
5.1 in both the the probe, no hybridization to parental VV DNA or to the
ative to the VV 0.6-kb fragment, which should contain only VV sequences,
h early and late was detected, whereas the 5.8-kb band apparently contained
NA sequences the neo gene (Fig. 3C). The orientation of neo within the
bined into the recombinants was determined by XhoI-RsaI double diges-
) the cytoplasm tion. If the gene were in the correct orientation this would
[on). Individual liberate a 469-base-pair fragment of neo, whereas in the
Lted by plaque opposite orientation a 700-bp fragment would be generated
urification. The (Fig. 2). The data (Fig. 3D) confirmed that isolated VV:NEO
iown in Fig. 3. recombinants contained the neo gene in both orientations.
rated with Sall Growth ofW:NEO in the presence of G418. The VV:NEO
ment present in recombinants were then tested for their ability, relative to
VV-NEO re- that of wild-type VV, to replicate in the presence of G418.
Since the treated cells were presumably in a fully inhibited
state, it was unclear whether sufficient neo-enc ded phos-
photransferase would be expressed to enable NgO to repli-
ui ui w w
cate. However, with G418 treatment sufficient to inhibit the
D > a a replication of wild-type VV by 99.1%, VV:REb was es-z z z z
sentially unaffected (Table 2). In contrast, VV:iO was
unable to grow, indicating the necessity for the neo gene to
be driven by a VV promoter for it to be functional in this
situation. Similarly, wild-type VV and VV:NEt were plated
2.0- on BSC-40 cells in the presence and absence of G418Fig.
4). In the absence of drug, both wild-type VV and VV:NEO
.6- formed plaques of normal size and morphology. In thei . presence of G418, wild-type VV could not form plaques,
-.94 whereas VV:NEO formed almost the same number of
_¢ plaques as on the control plate, although they were sli tl
smaller. This would indicate that the progeny VV:NEO
05- virions were able to spread from cell to cell and overcome
the G418-mediated inhibition in second- and third-generation
infections. VV:O behaved identically to wild-type VV in
these assays (data not shown).
Mechanism of G418 inhibition ofW replication. G418 is an
aminoglycoside antibiotic which inhibits eucaryotic protein
mbinants. DNAs synthesis by interfering with 80S ribosome function (2). Thus
3 were restricted it was of interest to investigate the mechanism by which this
sis (A). The DNA drug interfered with VV replication and how expression of
and probed with the neo gene alleviated the inhibition. One simple method
XA(C). Touconfirm useful for monitoring the course of a VV infection is to
As blot analyses examine the kinetics of viral protein synthesis. From the
The positions of patterns observed, inferences can be drawn about the ex-
n as markers are pression of early genes, viral DNA synthesis, late gene
expression, and protein-processing events. Therefore,
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TABLE 3. Effect of G418 on marker rescue efficiencya
G418 treatment during: Total VV No. (%) of
Marker rescue Amplification PFU positiverecombinants
-
- 1.0 x 108 4.0 x 105 (0.4)
- + 2.5 x 104 4.0 x 102 (1.6)
+ - 3.0 x 107 2.0 x 105 (0.7)
+ + 5.0 x 103 1.4 x 103 (28.0)
,,~ ~ 2
ri
n
X f ~~~~~~~d
ti
FIG. 4. VV plaque assays. Plaque assays were camed out in the s
presence or absence of G418 with wild-type (WT) VV and the two
VV:NEO recombinants. After 48 h the plaques were visualized by
n
staining the monolayers with methylene blue. Only results for n
wild-type VV and VV:IN are shown. F
monolayers of cells were infected with VV, VV:NRb, or a
VV:NEO in the presence of [35S]methionine, and the radio- e
actively labeled polypeptides were examined by polyacryl-
amide gel electrophoresis. Pulse-labeling was done both c
early (before DNA synthesis) and late (after DNA synthesis) e
during infection on cells that had been mock infected or i
A _- -_
MI VV WT VV NEO VV NEO
2h 7h 2h 7h 2h 7h 2h 7h
-
+ - +
-
+
IU -
~~~~~~~q--
00to 40Sts
*
_-+ -+ - + _-+ - +
W "
*
a pVV:NEO plasmid DNA was transfected into monolayers of VV-infected
BSC-40 cells (multiplicity of infection, 5 PFU/cell) with or without G418 (2
mg/ml). This initial marker rescue crude stock was amplified by a subsequent
passage (multiplicity of infection, 0.01 PFU/cell) with (for 48 h) and without
drug. The progeny virus titers were determined, and the viruses were
subjected to plaque hybridization with a neo-specific probe to detect neo-
containing recombinants.
infected with wild-type VV, VV:NEb, or VV: O. The
results (Fig. 5A) were immediately surprising. First, the
mock-infected cell extracts showed that there was very little
difference in the pattern of nascent polypeptides translated
with and without G418, even though previous experiments
had shown that cell growth was inhibited under these condi-
Lions. Second, both VV and the VV:NEO recombinants
were able to express both early and late viral genes, which
suggests that viral DNA synthesis had also occurred. How-
wver, a close examination of the pattern of viral proteins
made at late times revealed that although some VV late
proteins were made in normal amounts in VV- and
VV: E-infected cells, there was a distinct subset of late
gene products which were either absent or greatly reduced in
amount in the presence of G418. These differences were
Even more pronounced when continuous labeling was used
(Fig. 5B). Note in both cases that VV:N) was able to
owercome this defect and synthesize those polypeptides
even in the presence of G418. It is unclear whether G418
inhibition of VV late gene expression was expressed directly
B -M- __MI VV WT VVNEO VVNEO
- + - + - + - +
Kd
- - -~94
Kd 6
- 94 |Wi-
-37~~~~~~~~~~~~~~~3
-28 2W1 iE*;+ 7
.4 ^ -I
- II
FIG. 5. Effect of G418 on VV protein synthesis. Monolayers of infected cells were either continuously labeled or pulse-labeled at the
indicated time postinfection with [35S]methionine. Radioactive proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and autoradiography. (A) Pulse label; (B) continuous label. The positions of VV proteins run as molecular weight markers are
indicated (in kilodaltons). *, Late gene products that were either absent or greatly decreased in the presence of G418. MI, Mock infected.
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at the translational level or indirectly at the posttranslational
level (i.e., cleavage).
G418 enhancement of marker rescue efficiency. To ascer-
tain whether G418 selection could be used during the initial
marker rescue steps to raise the percentage of recombinants
obtained, the following experiment was performed. The
VV:NEO plasmid was transfected into recipient cells with
and without G418, the progeny of the initial rescue were
passaged one additional time (with and without drug selec-
tion), and the percentage of recombinant virions was deter-
mined by a combination of plaque assay and hybridization
protocols. Having G418 present during either the marker
rescue or amplification step resulted in a modest increase in
the efficiency of marker rescue, twofold and fourfold, re-
spectively (Table 3). However, when the drug was present
during both steps, a synergistic 70-fold increase in the
percentage of recombinants was observed.
DISCUSSION
These experiments have demonstrated that the antibiotic
G418 is an effective and potent inhibitor of VV replication in
mammalian cells. When cell monolayers are treated for 48 h
before infection with 2 mg of G418 per ml, the growth of VV
is inhibited by 95 to 99% and the ability of the virus to form
visible plaques is totally blocked. The G418-mediated inhibi-
tion is apparently due to a reduction in the expression of a
subset of VV late genes. In any case, the inhibition can be
overcome by introducing a bacterial neomycin resistance
gene into the VV genome so that it is regulated and ex-
pressed by a VV promoter. Such a recombinant (VV:NEZ)
is able to replicate, assemble, form plaques, and express its
entire genetic program in the presence of high levels of G418.
This information should be of immediate consequence as
far as using neo as a positive selectable marker to facilitate
the selection and isolation of VV recombinants containing
foreign genes of interest. There are at least two potential
avenues to pursue. First, it is possible that the pVV5.1:NEt
plasmid could be cotransfected into VV-infected cells along
with another gene which is in a different VV insertion vector
plasmid in the presence of G418. The second insertion vector
could contain either similar or dissimilar flanking VV DNA
sequences so long as they resulted in insertion in a non-
essential region. Cells which are competent for DNA uptake
should take up both plasmids. The neo gene will be ex-
pressed in those cells and allow a productive infection and
concomitant marker rescue to occur. Conversely, VV which
infect noncompetent cells will be unable to replicate in the
presence of G418. This procedure would use the neo gene to
convect other genes into the VV genome while reducing the
background of wild-type VV replication. Convection proce-
dures have previously been applied successfully in cellular
transformation studies (5) and to temperature-sensitive VV
mutants (9). A second approach would be to construct
dual-insertion vectors with the neo gene linked to a second
gene. This latter approach would have the potential advan-
tage of allowing VV recombinants to be selected directly
after the marker rescue procedure. Any virus able to form
plaques in the presence of G418 should contain the neo gene
as well as the passenger gene of interest. Since neo is a
bacterial gene and probably not significantly homologous to
any VV DNA sequences, such insertion vectors could be
tailored by virtue of their homologous VV DNA flanking
sequences to insert the foreign gene in any nonessential
region of the viral genome. Such plasmid constructions with
a variety of VV promoters and assayable foreign genes are
currently in progress.
In view of these results it is likely that genetic engineering
procedures may be used to construct VV insertion vectors
that use any of a number of selectable or easily detectable
marker systems. The availability of such plasmids should
greatly facilitate the use of VV as a general eucaryotic
cloning and expression vector. The ability to rapidly con-
struct a series of VV recombinants containing a foreign gene
of interest and genetically manipulated derivatives should
prove invaluable in this regard.
ACKNOWLEDGMENTS
This research was supported by funds from the Murdoch Trust
Foundation (to D.E.H.), by grants PCM-8316390 (to D.E.H.) and
DMB-8316856 (to J.H.S.) from the National Science Foundation, by
Public Health Service grants AI-10793 (to J.H.S.) and AI-20612 (to
J.H.S.) from the National Institutes of Health, and by Biomedical
Research Support grant 557 RR 07003.
We thank Richard Maki for useful discussions and his generous
gift of G418.
LITERATURE CITED
1. Bonner, W. M., and R. A. Laskey. 1974. A film detection
method for tritium-labeled proteins and nucleic acids in poly-
acrylamide gels. Eur. J. Biochem. 46:83-91.
2. Davies J., and A. Jimenez. 1980. A new selective agent for
eukaryotic cloning vectors. Am. J. Trop. Med. Hyg. 29:
1089-1092.
3. Davies, J., and D. I. Smith. 1978. Plasmid determined resistance
to antimicrobial agents. Annu. Rev. Microbiol. 32:469-518.
4. DeFillipes, F. M. 1982. Restriction enzyme mapping of vaccinia
virus DNA. J. Virol. 43:136-149.
5. Gazit, A., H. Igarashi, I. Chiu, A. Srinivasan, A. Yaniv, S.
Tronock, K. C. Robbins, and S. G. Aaronson. 1984. Expression
of the normal human sis/PDFG-2 coding sequence induces cell
transformation. Cell 39:89-97.
6. Graham, F. L., and A. J. Van der Eb. 1973. A new technique for
the assay of infectivity of human adenovirus 5 DNA. Virology
52:456-467.
7. Hruby, D. E., L. A. Guarino, and J. R. Kates. 1979. Vaccinia
virus replication. I. Requirement for the host cell nucleus. J.
Virol. 29:705-715.
8. Hruby, D. E., L. L. Lynn, and J. R. Kates. 1979. Vaccinia virus
replication requires active participation of the host cell tran-
scriptional apparatus. Proc. Natl. Acad. Sci. U.S.A. 76:
1887-1890.
9. Kieny, M. P., R. Lathe, R. Drilien, D. Spehner, S. Skory, D.
Schmitt, T. Wiktor, H. Koprowski, and J. P. Lecoq. 1984.
Expression of rabies virus glycoprotein from a recombinant
vaccinia virus. Nature (London) 312:163-166.
10. Lapata, M. A., D. W. Cleveland, and B. Sollner-Webb. 1984.
High expression of a chloramphenicol acetyl transferase gene
by DEAE-dextran mediated DNA transfection coupled with a
dimethyl sulfoxide or glycerol shock treatment. Nucleic Acids
Res. 12:5707-5717.
11. Mackett, M., G. L. Smith, and B. Moss. 1984. General method
for production and selection of infectious vaccinia virus re-
combinants expressing foreign genes. J. Virol. 49:857-864.
12. Moss, B. 1974. Reproduction of poxviruses, p. 405-474. In H.
Fraenkel-Conrat and R. R. Wagner (ed.), Comprehensive virol-
ogy, Vol. 3. Plenum Publishing Corp., New York.
13. Paoletti, E., B. R. Lipinskas, C. Samsonoff, S. Mercer, and D.
Panacali. 1974. Construction of live vaccines using genetically
engineered poxviruses: biological activity of vaccinia virus
recombinants expressing the hepatitus B virus surface antigen
and the herpes simplex virus glycoprotein D. Proc. Natl. Acad.
Sci. U.S.A. 81:193-197.
14. Sharp, P. A., B. Sugden, and J. Sambrook. 1973. Detection of
two restriction endonuclease activities in Haemophilus
parainfluenzae using analytical agarose. Biochemistry
12:3055-3061.
VOL. 5, 1985
MOL. CELL. BIOL.
15. Smith, G. L., M. Mackett, and B. Moss. 1983. Infectious
vaccinia virus recombinants that express hepatitis B virus
surface antigen. Nature (London) 302:490-495.
16. Smith, G. L., B. R. Murphy, and B. Moss. 1983. Construction
and characterization of an infectious vaccinia virus recombinant
that expresses the influenza hemagglutinin gene and induces
resistance to influenza virus infection in hamsters. Proc. Natl.
Acad. Sci. U.S.A. 80:7155-7159.
17. Southern, E. M. 1975. Detection of specific sequences among
DNA fragments separated by gel electrophoresis. J. Mol. Biol.
98:503-517.
18. Southern, P. J., and P. Berg. 1982. Transformation of mam-
malian cells to antibiotic resistance with a bacterial gene under
control of the SV40 early region promoter. J. Mol. Appl. Genet.
1:327-341.
19. Studier, F. W. 1973. Analysis of bacteriophage T7 early RNAs
and proteins on slab gels. J. Mol. Biol. 79:237-248.
20. Villarreal, L. P., and P. Berg. 1977. Hybridization in situ of
SV40 plaques: detection of recombinant SV40 virus carrying
specific sequences of nonviral DNA. Science 196:183-186.
21. Weir, J. P., G. Bajszar, and B. Moss. 1982. Mapping of the
vaccinia virus thymidine kinase gene by marker rescue and by
cell-free translation of selected mRNA. Proc. Natl. Acad. Sci.
U.S.A. 79:1219-1214.
1924 FRANKE ET AL.
